GLP‑1 weight‑loss drugs spur rise of mini desserts and pen design

Weight‑loss injections such as Ozempic, Wegovy, Mounjaro and Zepbound have generated more than US$ 40 billion in sales in 2024. Their rapid market growth is reshaping consumer habits, with users seeking indulgence in smaller portions to avoid excess calories. In Brazil, this trend has boosted demand for mini desserts, which allow a sweet treat without over‑indulgence and fit the “food‑therapy” desire for comfort without guilt.

The success of these drugs also hinges on the design of the injection pens. Designers have turned the complex therapy into a simple, weekly home‑use device, emphasizing ease of dose, hygiene and confidence. While the pens achieve high adoption, critics note that, unlike the democratic design of the Bic Cristal ballpoint, the GLP‑1 pens remain expensive and not fully accessible to all consumers.